So lets look at the $1B (assume it is AUD)
Relyvrio sales in 2023 were est at USD$380M <> AUD$587M
Relyvrio is ONLY available in the USA <> Monepantel seeking AU, EU, USA
Relyvrio had numerous customers drop off the treatment due to side effects <> Monepantel so far has very few adverse effects/well tolerated to date.
Relyvrio potential to extend life by average of 9 months (now not so true) <> Monepantel potentially double and more than than so the customer base per year increases (not passing away in 9 months, so on the treatment for much longer)
It may well be this statement that the ASX has taken as a please explain. We will see in time. I do think there is sufficient data to explain an AUD $1B potential annual sales but I can also see where the ASX is dubious too. Unlike us, I highly doubt they study the company fundamentals before demanding a please explain.
adreamer
- Forums
- ASX - By Stock
- PAA
- Ann: Trading Halt
Ann: Trading Halt, page-40
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $89.00M |
Open | High | Low | Value | Volume |
20.0¢ | 20.0¢ | 19.3¢ | $112.4K | 570.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 71364 | 19.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.0¢ | 457262 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 71364 | 0.195 |
17 | 559420 | 0.190 |
25 | 1012945 | 0.185 |
19 | 993658 | 0.180 |
9 | 728068 | 0.175 |
Price($) | Vol. | No. |
---|---|---|
0.200 | 407262 | 5 |
0.205 | 202546 | 7 |
0.215 | 206000 | 4 |
0.220 | 109118 | 1 |
0.225 | 62500 | 1 |
Last trade - 15.59pm 05/07/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |